talkbio – Page 11

Eli Lilly’s Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer

3 weeks ago talkbio0Tagged Approved, Carcinoma breast stage IV, Eli, Eli Lilly, EMBER-3 trial, ESR1 gene, Estrogen receptor positive, HER2-negative, Imlunestrant, Inluriyo, Mutation, Oral SERD, United States Food and Drug Administration

Eli Lilly; Inluriyo; oral SERD; imlunestrant; FDA approval; ESR1 mutation; metastatic breast cancer; estrogen receptor positive; HER2-negative; EMBER-3 trial

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

3 weeks ago talkbio0Tagged Commitment Deadline, direct-to-consumer sales, drug price, executive order, international reference price, Medicaid, MFN, Most-Favored-Nation, Parity, pharmaceutical manufacturers, Prices, Pricing, tariffs, Transplant Registry Unified Management Program

Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price

Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

3 weeks ago talkbio0Tagged Artificial Intelligence, cancer care, Healthcare technology, oncology ecosystem, orchestration, patient navigation, Series D, strategic investors, Thyme Care, unicorn startup, Value-Based Care

Thyme Care; cancer care; Series D funding; AI orchestration; oncology ecosystem; value-based care; patient navigation; strategic investors; unicorn startup; healthcare technology

Kai Beckmann Appointed as Successor to Merck KGaA CEO Belén Garijo, Effective May 2026

3 weeks ago talkbio0Tagged Belén Garijo, business career, CEO, Corporate, Electronic, Executive Board, governance, Health Care Sector, Kai Beckmann, Leadership Transition, Merck KGaA, strategic transformation, succession

Merck KGaA; Kai Beckmann; Belén Garijo; CEO Succession; Electronics Business; Executive Board; Leadership Transition; Healthcare sector; Corporate governance; Strategic transformation

AstraZeneca Appeals to Supreme Court in Final Attempt to Challenge Medicare Drug Price Negotiation Program

3 weeks ago talkbio0Tagged AstraZeneca, drug price, Farxiga, Inflation Reduction Act, Medicare, Myasthenic Syndromes, Congenital, Negotiation Program, Supreme Court

AstraZeneca; Medicare Drug Price Negotiation Program; Supreme Court; Inflation Reduction Act; Third Circuit; due process; pharmaceuticals; CMS; drug pricing; Farxiga

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

3 weeks ago talkbio0Tagged bimagrumab, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Obesity, regulatory strategy, tirzepatide, Trial Termination, Zepbound

Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

3 weeks ago talkbio0Tagged Evaluation, Manufacturing, Medical Devices, medtech industry, National Security, pharmaceutical imports, Sectioning technique, semiconductor tariffs, supply chain, tariffs, Transplant Registry Unified Management Program

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

3 weeks ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development

Catalent Opens New Global HQ; Fujifilm Launches North Carolina Factory

3 weeks ago talkbio0Tagged Biopharma, Catalent, Cell Culture Techniques, Fujifilm Biotechnologies, global headquarters, Holly Springs, Johnson and Johnson, Manufacturing Facilities, North Carolina, Tampa Florida

Catalent; Global Headquarters; Tampa Florida; Fujifilm Biotechnologies; North Carolina; Holly Springs; manufacturing facility; Johnson & Johnson; cell culture; biopharma

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

3 weeks ago talkbio0Tagged alpha 1-antitrypsin, Artificial Intelligence, Automation, Contraceptives, Oral, eli lilly, Obesity, orforglipron, pharmaceutical manufacturing, Supply Chain Resilience, Surgical construction, Texas Facility

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation